Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Total Debt (2018 - 2025)

Historic Total Debt for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $59.6 million.

  • TransMedics' Total Debt rose 52.11% to $59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 million, marking a year-over-year increase of 52.11%. This contributed to the annual value of $59.4 million for FY2024, which is 52.15% up from last year.
  • As of Q3 2025, TransMedics' Total Debt stood at $59.6 million, which was up 52.11% from $59.5 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Total Debt registered a high of $59.6 million during Q3 2025, and its lowest value of $34.8 million during Q1 2021.
  • For the 5-year period, TransMedics' Total Debt averaged around $51.5 million, with its median value being $58.9 million (2023).
  • In the last 5 years, TransMedics' Total Debt soared by 6698.04% in 2022 and then soared by 51.91% in 2025.
  • Quarter analysis of 5 years shows TransMedics' Total Debt stood at $35.2 million in 2021, then soared by 66.76% to $58.7 million in 2022, then rose by 0.63% to $59.1 million in 2023, then rose by 0.52% to $59.4 million in 2024, then grew by 0.39% to $59.6 million in 2025.
  • Its Total Debt was $59.6 million in Q3 2025, compared to $59.5 million in Q2 2025 and $59.4 million in Q1 2025.